Medical Aspects of Chemical Warfare (2008) - The Black Vault
Medical Aspects of Chemical Warfare (2008) - The Black Vault Medical Aspects of Chemical Warfare (2008) - The Black Vault
Medical DiagnosticsClHAsCCClClHaH 2OOHHAsCCOHClHbEDTPDTBALSCH 2SCH 2HClCAsC SHLogan (1999) 1CH 2HClCAsC SHWooten (2002) 2CH 2CH 2SCH 2HAsCCSCHClHCH 2OHcHFBISCH 2HAsFiddler (2000) 3CCSCHClHCH 2OC(O)C 3F 7Fig. 22-12. Published analytical approaches for the analysis of chlorovinylarsonous acid in urine. (a) Reaction of lewisite(trans isomer shown) with water to form chlorovinylarsonous acid. (b) Reactions of chlorovinylarsonous acid with thiolcompounds ethanedithiol, propanedithiol, and British anti-Lewisite. 1,2,3 (c) Derivatization using HFBI. 3BAL: British anti-LewisiteEDT: ethanedithiolH 2O: dihydrogen monoxide; waterHFBI: heptafluorobutyryl imidazolePDT: propanedithiolData sources: (1) Logan TP, Smith JR, Jakubowski EM, Nielson RE. Verification of lewisite exposure by the analysis of 2-chlorovinyl arsonous acid in urine. Toxicol Meth. 1999;9:275–284. (2) Wooten JV, Ashley DL, Calafat AM. Quantitation of 2-chlorovinylarsonous acid in human urine by automated solid-phase microextraction-gas chromatography-mass spectrometry.J Chromatogr B Analyt Technol Biomed Life Sci. 2002;772:147–153. (3) Fidder A, Noort D, Hulst AG, de Jong LP, Benschop HP.Biomonitoring of exposure to lewisite based on adducts to haemoglobin. Arch Toxicol. 2000;74:207–214.729
Medical Aspects of Chemical WarfareEXHIBIT 22-4SAMPLE PREPARATION METHODS FOR Gas Chromatographic/MassSpectrometric ANALYSIS OF chlorovinylarsonous acidSPE procedure of Logan et al for CVAA in urine:• Precondition a C18 SPE cartridge with methanol followed by water.• Adjust pH of 1 mL of urine to pH 6 using HCl.• Add PAO as an internal standard.• Transfer sample to C18 SPE cartridge for sample cleanup/extraction.• Elute analytes using methanol.• Evaporate to dryness under nitrogen.• Reconstitute with ethanol containing EDT.• Analyze using GC-MS with EI ionization. 1SPME headspace procedure of Wooten et al for CVAA in urine:• Place 1 mL of urine into a 10-mL vial.• Add ammonium acetate buffer-water solution.• Add PAO as an internal standard.• Add PDT in order to derivatize CVAA and PAO.• Crimp-seal vial and heat at 70°C for 20 min.• Insert a 100-μM poly(dimethylsiloxane) SPME fiber into the sample vial headspace for 10 min.• Remove the SPME fiber from the vial and insert into the injection port of a GC-MS with EI ionization. 2SPE procedure of Fidder et al for free and bound CVAA in blood:• Add 2,3-dimercapto-1-propanol (BAL) to a 2-mL blood sample. The BAL causes displacement of bound CVAAand derivatizes both the free and released CVAA.• Add phenylarsine-BAL as an internal standard.• Shake the sample at room temperature overnight.• Dilute the sample with water.• Transfer sample to C18 SPE cartridge for sample cleanup/extraction.• Elute the analytes from the cartridge using dichloromethane/acetonitrile mixture.• Concentrate the extracted sample to dryness.• Redissolve in toluene.• Add HFBI to derivatize the BAL hydroxyl group.• Incubate the sample for 1 hour at 50°C and then cool to room temperature.• Wash with water and then dry over MgSO 4.• Analyze using GC-MS with EI ionization. 3BAL: British anti-LewisiteCVAA: chlorovinylarsonous acidEDT: ethanedithiolEI: electron impactGC: gas chromatographyHCl: hydrochloric acidHFBI: heptafluorobutyryl imidazoleMS: mass spectrometryPAO: phenylarsine oxidePDT: 1,3-propanedithiolSPE: solid phase extractionSPME: solid phase microextractionData sources: (1) Logan TP, Smith JR, Jakubowski EM, Nielson RE. Verification of lewisite exposure by the analysis of 2-chlorovinylarsonous acid in urine. Toxicol Meth. 1999;9:275–284. (2) Wooten JV, Ashley DL, Calafat AM. Quantitation of 2-chlorovinylarsonousacid in human urine by automated solid-phase microextraction-gas chromatography-mass spectrometry. J Chromatogr B Analyt TechnolBiomed Life Sci. 2002;772:147–153. (3) Fidder A, Noort D, Hulst AG, de Jong LP, Benschop HP. Biomonitoring of exposure to lewisitebased on adducts to haemoglobin. Arch Toxicol. 2000;74:207–214.730
- Page 701 and 702: Medical Aspects of Chemical Warfare
- Page 703 and 704: Medical Aspects of Chemical Warfare
- Page 705 and 706: Medical Aspects of Chemical Warfare
- Page 707 and 708: Medical Aspects of Chemical Warfare
- Page 709 and 710: Medical Aspects of Chemical Warfare
- Page 711 and 712: Medical Aspects of Chemical Warfare
- Page 713 and 714: Medical Aspects of Chemical Warfare
- Page 715 and 716: Medical Aspects of Chemical Warfare
- Page 717 and 718: Medical Aspects of Chemical Warfare
- Page 719 and 720: Medical Aspects of Chemical Warfare
- Page 721 and 722: Medical Aspects of Chemical Warfare
- Page 723 and 724: Medical Aspects of Chemical Warfare
- Page 725 and 726: Medical Aspects of Chemical Warfare
- Page 727 and 728: Medical Aspects of Chemical Warfare
- Page 729 and 730: Medical Aspects of Chemical Warfare
- Page 731 and 732: Medical Aspects of Chemical Warfare
- Page 733 and 734: Medical Aspects of Chemical Warfare
- Page 735 and 736: Medical Aspects of Chemical Warfare
- Page 737 and 738: Medical Aspects of Chemical Warfare
- Page 739 and 740: Medical Aspects of Chemical Warfare
- Page 741 and 742: Medical Aspects of Chemical Warfare
- Page 743 and 744: Medical Aspects of Chemical Warfare
- Page 745 and 746: Medical Aspects of Chemical Warfare
- Page 747 and 748: • Analyze using GC-MS with methan
- Page 749 and 750: Medical Aspects of Chemical Warfare
- Page 751: Medical Aspects of Chemical Warfare
- Page 755 and 756: Medical Aspects of Chemical Warfare
- Page 757 and 758: Medical Aspects of Chemical Warfare
- Page 759 and 760: Medical Aspects of Chemical Warfare
- Page 761 and 762: Medical Aspects of Chemical Warfare
- Page 763 and 764: Medical Aspects of Chemical Warfare
- Page 765 and 766: Medical Aspects of Chemical Warfare
- Page 767 and 768: Medical Aspects of Chemical Warfare
- Page 769 and 770: Medical Aspects of Chemical Warfare
- Page 771 and 772: Medical Aspects of Chemical Warfare
- Page 773 and 774: Medical Aspects of Chemical Warfare
- Page 775 and 776: Medical Aspects of Chemical Warfare
- Page 777 and 778: Medical Aspects of Chemical Warfare
- Page 779 and 780: Medical Aspects of Chemical Warfare
- Page 781 and 782: Medical Aspects of Chemical Warfare
- Page 783 and 784: Medical Aspects of Chemical Warfare
- Page 785 and 786: Medical Aspects of Chemical Warfare
- Page 787 and 788: Medical Aspects of Chemical Warfare
- Page 789 and 790: Medical Aspects of Chemical Warfare
- Page 791 and 792: Medical Aspects of Chemical Warfare
- Page 793 and 794: Medical Aspects of Chemical Warfare
- Page 795 and 796: Medical Aspects of Chemical Warfare
- Page 798 and 799: Abbreviations and AcronymsAbBreviat
- Page 800: Abbreviations and AcronymsPADPRP: p
<strong>Medical</strong> <strong>Aspects</strong> <strong>of</strong> <strong>Chemical</strong> <strong>Warfare</strong>EXHIBIT 22-4SAMPLE PREPARATION METHODS FOR Gas Chromatographic/MassSpectrometric ANALYSIS OF chlorovinylarsonous acidSPE procedure <strong>of</strong> Logan et al for CVAA in urine:• Precondition a C18 SPE cartridge with methanol followed by water.• Adjust pH <strong>of</strong> 1 mL <strong>of</strong> urine to pH 6 using HCl.• Add PAO as an internal standard.• Transfer sample to C18 SPE cartridge for sample cleanup/extraction.• Elute analytes using methanol.• Evaporate to dryness under nitrogen.• Reconstitute with ethanol containing EDT.• Analyze using GC-MS with EI ionization. 1SPME headspace procedure <strong>of</strong> Wooten et al for CVAA in urine:• Place 1 mL <strong>of</strong> urine into a 10-mL vial.• Add ammonium acetate buffer-water solution.• Add PAO as an internal standard.• Add PDT in order to derivatize CVAA and PAO.• Crimp-seal vial and heat at 70°C for 20 min.• Insert a 100-μM poly(dimethylsiloxane) SPME fiber into the sample vial headspace for 10 min.• Remove the SPME fiber from the vial and insert into the injection port <strong>of</strong> a GC-MS with EI ionization. 2SPE procedure <strong>of</strong> Fidder et al for free and bound CVAA in blood:• Add 2,3-dimercapto-1-propanol (BAL) to a 2-mL blood sample. <strong>The</strong> BAL causes displacement <strong>of</strong> bound CVAAand derivatizes both the free and released CVAA.• Add phenylarsine-BAL as an internal standard.• Shake the sample at room temperature overnight.• Dilute the sample with water.• Transfer sample to C18 SPE cartridge for sample cleanup/extraction.• Elute the analytes from the cartridge using dichloromethane/acetonitrile mixture.• Concentrate the extracted sample to dryness.• Redissolve in toluene.• Add HFBI to derivatize the BAL hydroxyl group.• Incubate the sample for 1 hour at 50°C and then cool to room temperature.• Wash with water and then dry over MgSO 4.• Analyze using GC-MS with EI ionization. 3BAL: British anti-LewisiteCVAA: chlorovinylarsonous acidEDT: ethanedithiolEI: electron impactGC: gas chromatographyHCl: hydrochloric acidHFBI: heptafluorobutyryl imidazoleMS: mass spectrometryPAO: phenylarsine oxidePDT: 1,3-propanedithiolSPE: solid phase extractionSPME: solid phase microextractionData sources: (1) Logan TP, Smith JR, Jakubowski EM, Nielson RE. Verification <strong>of</strong> lewisite exposure by the analysis <strong>of</strong> 2-chlorovinylarsonous acid in urine. Toxicol Meth. 1999;9:275–284. (2) Wooten JV, Ashley DL, Calafat AM. Quantitation <strong>of</strong> 2-chlorovinylarsonousacid in human urine by automated solid-phase microextraction-gas chromatography-mass spectrometry. J Chromatogr B Analyt TechnolBiomed Life Sci. 2002;772:147–153. (3) Fidder A, Noort D, Hulst AG, de Jong LP, Benschop HP. Biomonitoring <strong>of</strong> exposure to lewisitebased on adducts to haemoglobin. Arch Toxicol. 2000;74:207–214.730